Entirely new drug for Alzheimer’s now being tested on patients

Sep 24, 2010 By Anneli Waara

An entirely new type of pharmaceutical substance for Alzheimer’s disease developed by Uppsala scientists is now starting to be clinically tested in the US. It attacks the early stage of the protein filaments that cause the disorder, so-called protofibrills.

“It would be a giant step forward to have a drug that actually targets the fundamental cause, as opposed to merely alleviating the symptoms, as today’s medicines do,” says Lars Lannfelt, professor of geriatrics at Uppsala University.

Lars Lannfelt is very optimistic. This is the first time a substance that directly attacks protofibrills is being clinically tested. The drug was developed in collaboration with the small Swedish biotech company BioArctic Neuroscience AB and the Japanese drug company Eisai. Just over 80 Alzheimer’s patients are included in the clinical trial.

Alzheimer’s disease is characterized by abnormal protein build-up in the brain, so-called plaques. They consist of long strands of , fibrills. The Uppsala researchers have previously shown that the prime danger is the pre-stage of these filaments, and they have therefore focused their research on finding a drug candidate, a monoclonal antibody, that specifically targets the pre-stage, so-called protofibrills.

“One of these , mAb158, has proven to completely inhibit the disease in mice,” says Lars Lannfelt.

The antibody has since been further developed to reduce the risk of triggering a reaction from the human , and in a few years the scientists will find out whether it has the same positive impact on humans as on mice. If the results are positive, the next step will be to involve considerably more patients.

Explore further: Deaths from narcotic painkillers quadrupled in past decade, CDC reports

add to favorites email to friend print save as pdf

Related Stories

Major breakthrough may pave the way for therapeutic vaccines

Dec 17, 2009

It should be possible to use therapeutic vaccines to create both cheap and effective drugs for diseases like cancer and allergies. One problem in developing such vaccines has previously been the lack of adjuvants, substances ...

An Alzheimer's vaccine?

Nov 12, 2007

Could a new vaccine be the key to stopping Alzheimer’s disease? A new research study from the Oklahoma Medical Research Foundation (OMRF) shows that immunization could offer a way to blunt or even prevent the deadly, memory-robbing ...

Recommended for you

US experts skeptical of testosterone drug benefits

11 minutes ago

U.S. health experts say there is little evidence that testosterone-boosting drugs are effective for treating common signs of aging and large studies are needed to support their continued use in millions of American men.

Big cities take aim at prescription painkillers

Sep 16, 2014

Some of the nation's largest cities are ratcheting up their criticism of prescription painkillers, blaming the industry for a wave of addiction and overdoses that have ravaged their communities and busted local budgets.

World Health Organization policy improves use of medicines

Sep 16, 2014

In this issue of PLOS Medicine, Kathleen Holloway from WHO and David Henry (University of Toronto, Canada) evaluated data on reported adherence to WHO essential medicines practices and measures of quality use of medicines from 5 ...

User comments : 0